cbio, page-2

Great post Matakus. I hope you're right, both from a patient view, and from us greedy shareholders:) Also, one or two booming successes, like this might be, will really boost investor interest in biotech shares and further improve the reputation of Australian biotech research.

I still have some caution though. Mainly because I heard that it was a drug that CSL looked at but did not take up. Albeit, the one they did take up (Gardasil) did okay. Also, the big disappointment when the first "big pharma" reviewed the results of the initial trial and walked. Back then people were talking about it being a $2 billion company, so I hope it eventually makes it.

As a share, I look at it like an oil and gas company drilling in elephant country - big risk, but huge reward potential. I recommend the investor research reports on the company Web site.